Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RVNC
DateTimeSourceHeadlineSymbolCompany
12/07/20178:30AMBusiness WireRevance Announces Pricing of Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
12/05/20175:30PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:RVNCRevance Therapeutics Inc
12/05/20174:45PMBusiness WireRevance Announces Proposed Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
12/05/20174:43PMEdgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:RVNCRevance Therapeutics Inc
12/05/20174:32PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVNCRevance Therapeutics Inc
12/05/20177:37AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVNCRevance Therapeutics Inc
12/05/20177:30AMBusiness WireRevance’s RT002 Meets Primary & All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Gla...NASDAQ:RVNCRevance Therapeutics Inc
11/29/20174:05PMBusiness WireRevance Plans Phase 3 Program for RT002 Injectable to Treat Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
11/24/20174:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RVNCRevance Therapeutics Inc
11/20/20174:05PMBusiness WireRevance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
11/03/20174:31PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RVNCRevance Therapeutics Inc
11/02/20174:22PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVNCRevance Therapeutics Inc
11/02/20174:05PMBusiness WireRevance Releases Third Quarter 2017 ResultsNASDAQ:RVNCRevance Therapeutics Inc
10/18/20174:05PMBusiness WireRevance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017NASDAQ:RVNCRevance Therapeutics Inc
10/18/20178:00AMBusiness WireRevance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar FasciitisNASDAQ:RVNCRevance Therapeutics Inc
09/19/20174:05PMBusiness WireRevance to Participate in the Cantor Fitzgerald 2017 Global Healthcare ConferenceNASDAQ:RVNCRevance Therapeutics Inc
09/06/20174:33PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVNCRevance Therapeutics Inc
09/06/20177:30AMBusiness WireRevance Appoints Mark Foley to its Board of DirectorsNASDAQ:RVNCRevance Therapeutics Inc
08/30/20174:05PMBusiness WireRevance to Participate in the 2017 Wells Fargo Securities Healthcare ConferenceNASDAQ:RVNCRevance Therapeutics Inc
08/25/20177:42PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RVNCRevance Therapeutics Inc
08/04/20175:10PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RVNCRevance Therapeutics Inc
08/03/20174:14PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVNCRevance Therapeutics Inc
08/03/20174:05PMBusiness WireRevance Releases Second Quarter 2017 ResultsNASDAQ:RVNCRevance Therapeutics Inc
08/02/20175:06PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVNCRevance Therapeutics Inc
08/01/20174:05PMBusiness WireRevance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer & President, Aesthetics & Th...NASDAQ:RVNCRevance Therapeutics Inc
07/24/20174:05PMBusiness WireRevance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017NASDAQ:RVNCRevance Therapeutics Inc
06/15/20178:00AMBusiness WirePositive BELMONT Phase 2 Trial Results Published in Dermatologic SurgeryNASDAQ:RVNCRevance Therapeutics Inc
06/06/20178:04AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVNCRevance Therapeutics Inc
06/05/20174:10PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RVNCRevance Therapeutics Inc
06/05/20174:05PMBusiness WireRevance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia TrialNASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC